The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 1, 2009, Pages 63-71

  McBride, Brian F ^a,b   Yang, Tao ^c   Liu, Kai ^c   Urban, Thomas J ^d   Giacomini, Kathleen M ^d   Kim, Richard B ^c   Roden, Dan M ^c,e   Oates, John A ^e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Oates Institute for Experimental Therapeutics   (United States)

Author keywords

Antiarrhythmia agents; Arrhythmia; Ion channels; Pharmacokinetics; Pharmacology

Indexed keywords

ERYTHROMYCIN; FLECAINIDE; I KAPPA B; IBUTILIDE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; POTASSIUM CHANNEL HERG; QUINIDINE; SLC22A4 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG TRANSPORT; HEART ARRHYTHMIA; HEART ATRIUM; HEART FUNCTION; HEART VENTRICLE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CATION TRANSPORT PROTEINS; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; FLECAINIDE; GENE EXPRESSION; HEART; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INHIBITORY CONCENTRATION 50; MYOCYTES, CARDIAC; ORGANIC CATION TRANSPORT PROTEINS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; QUINIDINE; SULFONAMIDES;

EID: 68249160805     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181abc288     Document Type: Article

References (50)

1. Jazwinska-Tarnawska EO, Echowska-Juzwenko K, Niewinski P, et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Int J Clin Pharmacol Ther. 2001;39: 288-292. (Pubitemid 32611526)
2. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260-277. (Pubitemid 41254111)
3. Wilkinson GR. Drug Metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
4. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study. J Infect Dis. 2005;192: 1931-1942.
5. Woodahl EL, Yang Z, Bui T, et al. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther. 2004;310:1199-1207. (Pubitemid 39108942)
6. Schinkel AH, Wagenaar E, Mol CAAM, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517-2524. (Pubitemid 26187339)
7. Sadeque AJM, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-237.
8. Roden DM, Balser JR, George AL Jr, et al. Cardiac ion channels. Ann Rev Physiol. 2002;64:431-475.
9. Zhou M, Morais-Cabral JH, Mann S, et al. Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature. 2001; 411:657-661. (Pubitemid 32531662)
10. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. PNAS. 2000;97:12329-12333. (Pubitemid 30815185)
11. Yeola SW, Rich TC, Uebele VN, et al. Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel: role of S6 in antiarrhythmic drug binding. Circ Res. 1996;78:1105-1114.
12. MacKinnon R, Yellen G. Mutations affecting TEA blockade and ion permeation in voltage-activated K+ channels. Science. 1990;250: 276-279. (Pubitemid 120031752)
13. Schuster A, Lacinova L, Klugbauer N, et al. The IVS6 segment of the L-type calcium channel is critical for the action dihydropyridines and phenylalkylamines. EMBO J. 1996;15:2365-2370. (Pubitemid 26156562)
14. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002; 105:1943-1948. (Pubitemid 34437622)
15. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997;96: 2778-2781. (Pubitemid 27500069)
16. Priori SG, Napolitano C, Schwartz PJ, et al. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529-533. (Pubitemid 29061868)
17. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000;11:691-696. (Pubitemid 30397542)
18. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287: 2215-2220.
19. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-1874.
20. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216-1231.
21. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993; 270:2590-2597.
22. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. PACE. 1998;21:1044-1057. (Pubitemid 28225859)
23. Gbadebo TD, Trimble RW, Khoo MSC, et al. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation. 2002;105:770-774.
24. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000;35:778-786. (Pubitemid 30167037)
25. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol. 2000;115:229-240. (Pubitemid 30695112)
26. Perry M, Stansfeld PJ, Leaney J, et al. Drug binding interactions in the inner cavity of hERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol. 2006;69: 509-519. (Pubitemid 43121948)
27. Grégoire D, Christine F, Patrick H, et al. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res. 2006;V23: 1525-1532.
28. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004;145:4384-4391.
29. Hebert MF, Dowling ALS, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) geneotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics. 2003;13:661-674. (Pubitemid 38316510)
30. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001;297:861-867. (Pubitemid 32472480)
31. Dalton TP, He L, Wang B, et al. Identification of mouse SLC39A8 as the transporter responsible for cadmium-induced toxicity in the testis. PNAS. 2005;102:3401-3406. (Pubitemid 40328057)
32. Sata R, Ohtani H, Tsujimoto M, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther. 2005;315:888-895. (Pubitemid 41500755)
33. Grube M, Meyer zu Schwabedissen HEU, Prager D, et al. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation. 2006;113:1114-1122.
34. Yabuuchi H, Tamai I, Nezu JI, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999;289:768-773. (Pubitemid 29191230)
35. Urban TJ, Giacomini KM, Risch N. Haplotype structure and ethnicspecific allele frequencies at the OCTN locus: implications for the genetics of Crohn's disease. Inflamm Bowel Dis. 2005;11:78-79. (Pubitemid 40340259)
36. Yang T, Snyders D, Roden DM. Drug block of IKr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38: 737-744. (Pubitemid 32983280)
37. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-Glycoprotein mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99:552-557.
38. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42:1501-1506. (Pubitemid 34020086)
39. Tishler D, Weingberg K, Hinton D, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36:1-6.
40. Clinckers R, Smolders I, Meurs A, et al. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther. 2005;314:725-731. (Pubitemid 41043855)
41. Kamiya K, Niwa R, Mitcheson JS, et al. Molecular determinants of hERG channel block. Mol Pharmacol. 2006;69:1709-1716.
42. Du LP, Li MY, Tsai KC, et al. Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochem Biophys Res Commun. 2005;332:677-687.
43. Drolet B, Simard C, Mizoue L, et al. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest. 2005;115:2209-2213. (Pubitemid 41134163)
44. Nisimura M, Naito S. Tissue specific mRNA expression profiles of human ATP binding cassette and solute carrier superfamilies. Drug Metab Pharmacokinet. 2005;20:452-477.
45. Wu X, George RL, Huang W, et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta Biomembr. 2000; 1466:315-327. (Pubitemid 30312986)
46. di San Filippo CA, Wang Y, Longo N. Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency. J Biol Chem. 2003;278:47776-47784. (Pubitemid 37523224)
47. Suhre WM, Ekins S, Chang C, et al. Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol. 2005;67:1067-1077. (Pubitemid 40410407)
48. Zhang X, Groves CE, Bahn A, et al. Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubule. Am J Physiol Renal Physiol. 2004;287:F999-F1010. (Pubitemid 39391097)
49. Zhang X, Shirahatti NV, Mahadevan D, et al. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J Biol Chem. 2005;280: 34813-34822. (Pubitemid 41504615)
50. + channel Kv1.5 by a human heart organic cation uptake transporter (OCTN1). Biophysics. 2006;90:2574.